Centre Regional Lutte Contre Le Cancer — Clinical Trial Site

56 Registered trials

29 Currently recruiting

Organisation

Centre Regional Lutte Contre Le Cancer

Location

Strasbourg, France

Identifier

ORG-100054755

Address

Batiment Icans, 17 Rue Albert Calmette, 67200, France

Departments

#1004: Medical Oncology
#2101: Nuclear Medecine
#2155A; Oncologie
033013: Oncology
4005: Oncologie medicale
Gastro - entérologie
Gastroenterology
Médecine nucléaire
Medical oncolgy
Medical Oncology
N/A
Nuclear medicine
oncologie
Oncologie médicale
Oncology
radiotherapie
Radiotherapy
Service de pathologie mammaire
Service de radiothérapie
Service oncologie medicale

Clinical trials at this site (56)

Search interface

Study of the effect and tolerability of INT230-6 by direct injection into the tumor, followed by neoadjuvant treatment with chemoimmunothera… Pending

2024-512511-49-00 Early triple-negative breast cancer (TNBC) 4
Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants With Ad… Pending

2025-521221-32-00 Advanced or Metastatic Non-Small Cell Lung Cancer 5
Study evaluating two treatment strategies for rectal cancer in patients ≥75 years old Pending

2025-521619-37-00 Patients ≥75 years old with cT3/T4 rectal adenocarcinom 5
Skipping Hormone Therapy in Low-Risk Early Breast Cancer Pending

2025-523683-20-00 Postmenopausal patients with small (pT1a-b pN0) hormone 4
Phase 3 study comparing ivonescimab alone or ivonescimab with ligufalimab versus pembrolizumab for the first-line treatment of recurrent and… Recruiting

2025-522996-27-00 recurrent and/or metastatic squamous cell carcinoma of 5 2026-05-05
ROSETTA Breast-01: The effects and safety of pumitamig in patients with triple-negative breast cancer Recruiting

2025-521884-12-00 First line triple-negative breast cancer (TNBC) 5 2026-03-19
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C… Recruiting

2024-515445-42-00 Node-positive, Estrogen Receptor-positive, HER2-negativ 5 2025-03-24
Study of Taxane-Platinum followed by a maintenance with avelumab and cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma… Recruiting

2023-510559-41-00 Recurrent or Metastatic Squamous Cell Carcinoma of the 4 2026-06-15
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizu… Recruiting

2025-521587-35-00 Metastatic colorectal cancer 5 2026-06-03
Visugromab in Cachexia International Trial Recruiting

2025-523533-25-00 Cancer-associated Cachexia 10 2026-03-26
IFCT-2401 SPORADIC a multicenter randomized open label phase II study evaluating the efficacy and the tolerance of adding cemiplimab to Sequ… Recruiting

2024-517316-29-00 Unresectable stage III Non-Small Cell Lung Cancer 4 2025-11-07
A trial to see if ficerafusp alfa given with pembrolizumab can treat participants with head and neck cancer. Recruiting

2024-519654-37-00 Recurrent or Metastatic Head and Neck Squamous Cell Car 10 2025-11-07
Testing ivonescimab in combination with standard chemotherapy in advanced or metastatic gastric and gastroesophageal adenocarcinoma patients Recruiting

2025-520694-39-00 Metastatic or locally advanced irresectable (stage IV) 4 2025-10-24
Influence des caractéristiques morphologiques sur la pharmacocinétique et la toxicité du trastuzumab-déruxtécan chez des patients ayant un c… Recruiting

2025-522656-68-00 Metastatic breast cancers 6 2025-10-15
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esoph… Recruiting

2023-509630-19-00 Esophageal Squamous Cell Carcinoma (ESCC) 5 2025-07-31
Safety, efficacy, and pharmacokinetics of BNT327 in combination with chemotherapy and other investigational agents for lung cancer Recruiting

2024-515764-31-00 Non-small cell lung cancer 10 2025-06-13
Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus … Recruiting

2024-513122-27-00 Unresectable, Locally Advanced or Metastatic HER2 posit 5 2025-06-10
Corticodependent or corticoresistant brain radionecrosis after radiotherapy for brain metastases: a multicentre randomized, controlled doub… Recruiting

2024-510893-25-00 Brain metastases of cancer > brain radionecrosis 5 2025-04-29
Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag… Recruiting

2023-509787-15-00 Patients with localised prostate cancer and high-risk f 5 2025-02-17
Decreasing treatment for metastatic HER2-Positive Breast Cancer with undetectable cancer levels in blood tests Recruiting

2023-509811-98-00 Patients with HER2-positive locally advanced inoperable 4 2025-01-07
A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with phys… Recruiting

2023-508960-31-00 Metastatic HER2-positive breast cancer 5 2024-12-03
Carboplatin + Paclitaxel + Cetuximab (PCC) after failure of first line Immune checkpoint inhibitor with or without chemotherapy in recurrent… Recruiting

2024-512297-96-01 Head and neck squamous cell carcinoma 4 2024-11-26
FIRST LINE CHEMOTHERAPY FOR METASTATIC GASTRO ENTERO PANCREATIC NEUROENDOCRINE CARCINOMA Recruiting

2024-515300-39-00 METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE 4 2024-10-18
PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II Recruiting

2024-515297-27-00 colon carcinoma 5 2024-08-14